🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06061185
Recruiting Observational

Multimodal Computed Tomography in Patients With Acute Hemorrhagic Stroke

NCT06061185 · tracked via the Priya Life Science China tracker
Sponsor
Xiaolin Chen, MD
Phase
Observational
Started
2020-01-01
Last updated
2025-04-04

Condition(s) studied

Acute Hemorrhagic Stroke

Investigational drug(s) / intervention(s)

Multimodal CT

Multimodal CT: Non-contrast computed tomography, computed tomography angiography and computed tomography perfusion

Study summary

Acute hemorrhagic stroke is a series of neurosurgical diseases characterized by bleeding with high morbidity and mortality. It accounts for about 20% of all strokes worldwide and mainly includes subtypes such as intracerebral hemorrhage (ICH) and subarachnoid hemorrhage (SAH). Multimodal computed tomography including non-contrast computed tomography, computed tomography angiography and computed tomography perfusion, is of great important in understanding pathophysiological changes, evaluating prognosis and guiding interventions in these diseases.

Eligibility

Sex
ALL
Min age
18 Years
Max age
85 Years
Healthy volunteers
Accepted
Inclusion Criteria: 1. age ≥ 18, ≤ 85 years; 2. presence with hemorrhagic stroke Exclusion Criteria: 1. with a history of previous history of ischemic/hemorrhagic stroke; 2. admission to the emergency department more than a week after symptom onset; 3. serious medical history or existing comorbidities; 4. physical disability due to previous diseases; 5. prior treatment such as external ventricular drainage, digital subtraction angiography and lumbar puncture in other institution; 6. poor original image quality; 7. incomplete follow-up.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Beijing Tiantan Hospital Beijing Beijing Municipality Recruiting

More Xiaolin Chen, MD trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06061185 on ClinicalTrials.gov ↗ ← All trials in China